Evidence map›Paper›PMID 37609007›Full record

ArticleMicrosystems & nanoengineering2023

A microfluidic biosensor for the diagnosis of chronic wasting disease.

Sura A Muhsin, Amjed Abdullah, Estela Kobashigawa, Muthana Al-Amidie, Sherri Russell, Michael Z Zhang, Shuping Zhang, Mahmoud Almasri

Open access · goldAbstract read
In one paragraph

Article in Microsystems & nanoengineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sura A MuhsinUniversity of Missouri-Columbia, Electrical Engineering and Computer Science, Columbia, MO USA.
Amjed AbdullahUniversity of Missouri-Columbia, Electrical Engineering and Computer Science, Columbia, MO USA.
Estela KobashigawaUniversity of Missouri-Columbia, College of Veterinary Medicine, Veterinary Medical Diagnostic Laboratory, Columbia, MO USA.
Muthana Al-AmidieUniversity of Missouri-Columbia, Electrical Engineering and Computer Science, Columbia, MO USA.
Sherri RussellMissouri Department of Conservation, Columbia, MO USA.
Michael Z ZhangUniversity of Missouri-Columbia, College of Veterinary Medicine, Veterinary Medical Diagnostic Laboratory, Columbia, MO USA.
Shuping ZhangUniversity of Missouri-Columbia, College of Veterinary Medicine, Veterinary Medical Diagnostic Laboratory, Columbia, MO USA.
Mahmoud AlmasriUniversity of Missouri-Columbia, Electrical Engineering and Computer Science, Columbia, MO USA.
University of Missouri · USMissouri College · USMissouri Department of Conservation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervids are affected by a neurologic disease that is always fatal to individuals and has population effects. This disease is called chronic wasting disease (CWD) and is caused by a misfolded prion protein. The disease is transmitted via contact with contaminated body fluids and tissue or exposure to the environment, such as drinking water or food. Current CWD diagnosis depends on ELISA screening of cervid lymph nodes and subsequent immunohistochemistry (IHC) confirmation of ELISA-positive results. The disease has proven to be difficult to control in part because of sensitivity and specificity issues with the current test regimen. We have investigated an accurate, rapid, and low-cost microfluidic microelectromechanical system (MEMS) biosensing device for the detection of CWD pathologic prions in retropharyngeal lymph nodes (RLNs), which is the current standard type of CWD diagnostic sample. The device consists of three novel regions for concentrating, trapping, and detecting the prion. The detection region includes an array of electrodes coated with a monoclonal antibody against pathologic prions. The experimental conditions were optimized using an engineered prion control antigen. Testing could be completed in less than 1 hour with high sensitivity and selectivity. The biosensor detected the engineered prion antigen at a 1:24 dilution, while ELISA detected the same antigen at a 1:8 dilution. The relative limit of detection (rLOD) of the biosensor was a 1:1000 dilution of a known strong positive RLN sample, whereas ELISA showed a rLOD of 1:100 dilution. Thus, the biosensor was 10 times more sensitive than ELISA, which is the currently approved CWD diagnostic test. The biosensor's specificity and selectivity were confirmed using known negative RPLN samples, a negative control antibody (monoclonal antibody against bovine coronavirus BCV), and two negative control antigens (bluetongue virus and Epizootic hemorrhagic disease virus). The biosensor's ability to detect pathogenic prions was verified by testing proteinase-digested positive RLN samples.

Indexed as

Electrical and electronic engineeringNanoparticles

Identifiers

PMID37609007
PMCPMC10440343
OpenAlexW4386030020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.